FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2974335763> ?p ?o ?g. }

• W2974335763 abstract "Abstract Background The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy in patients with hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed. Methods Postmenopausal women with untreated stage I–III HR+/HER2-negative breast cancer were randomized (1:1:1) to receive 3 weeks of letrozole (LTZ) 2.5 mg/day, oral mVNB 50 mg 3 days/week, or the combination. The primary objective was to evaluate, within PAM50 Luminal A/B disease, if the anti-proliferative effect of LTZ+mVNB was superior to monotherapy. An anti-proliferative effect was defined as the mean relative decrease of the PAM50 11-gene proliferation score in combination arm vs. both monotherapy arms. Secondary objectives included the evaluation of a comprehensive panel of breast cancer-related genes and safety. An unplanned analysis of stromal tumor-infiltrating lymphocytes (sTILs) was also performed. PAM50 analyses were performed using the nCounter®-based Breast Cancer 360™ gene panel, which includes 752 genes and 32 signatures. Results Sixty-one patients were randomized, and 54 paired samples (89%) were analyzed. The main patient characteristics were mean age of 67, mean tumor size of 1.7 cm, mean Ki67 of 14.3%, stage I (55.7%), and grades 1–2 (90%). Most baseline samples were PAM50 Luminal A (74.1%) or B (22.2%). The anti-proliferative effect of 3 weeks of LTZ+mVNB (− 73.2%) was superior to both monotherapy arms combined (− 49.9%; p = 0.001) and mVNB (− 19.1%; p < 0.001). The anti-proliferative effect of LTZ+mVNB (− 73.2%) was numerically higher compared to LTZ (− 65.7%) but did not reach statistical significance ( p = 0.328). LTZ+mVNB induced high expression of immune-related genes and gene signatures, including CD8 T cell signature and PDL1 gene and low expression of ER-regulated genes (e.g., progesterone receptor) and cell cycle-related and DNA repair genes. In tumors with ≤ 10% sTILs at baseline, a statistically significant increase in sTILs was observed following LTZ (paired analysis p = 0.049) and LTZ+mVNB ( p = 0.012). Grade 3 adverse events occurred in 3.4% of the cases. Conclusions Short-term mVNB is well-tolerated and presents anti-proliferative activity alone and in combination with LTZ. The high expression of immune-related biological processes and sTILs observed with the combination opens the possibility of studying this combination with immunotherapy. Further investigation comparing these biological results with other metronomic schedules or drug combinations is warranted. Trial registration NCT02802748 , registered 16 June 2016." @default.
• W2974335763 created "2019-09-26" @default.
• W2974335763 creator A5004725639 @default.
• W2974335763 creator A5006511628 @default.
• W2974335763 creator A5010152267 @default.
• W2974335763 creator A5016401289 @default.
• W2974335763 creator A5019569585 @default.
• W2974335763 creator A5025238669 @default.
• W2974335763 creator A5025842545 @default.
• W2974335763 creator A5042649658 @default.
• W2974335763 creator A5043895722 @default.
• W2974335763 creator A5051034956 @default.
• W2974335763 creator A5059201728 @default.
• W2974335763 creator A5062635658 @default.
• W2974335763 creator A5073139685 @default.
• W2974335763 creator A5075479450 @default.
• W2974335763 creator A5077463490 @default.
• W2974335763 creator A5080122151 @default.
• W2974335763 creator A5088693169 @default.
• W2974335763 creator A5089513581 @default.
• W2974335763 creator A5089555041 @default.
• W2974335763 date "2019-09-18" @default.
• W2974335763 modified "2023-10-15" @default.
• W2974335763 title "Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial" @default.
• W2974335763 cites W1508743943 @default.
• W2974335763 cites W1878299132 @default.
• W2974335763 cites W1972146805 @default.
• W2974335763 cites W1973091654 @default.
• W2974335763 cites W1979066871 @default.
• W2974335763 cites W1981667867 @default.
• W2974335763 cites W2026902309 @default.
• W2974335763 cites W2044702943 @default.
• W2974335763 cites W2061401090 @default.
• W2974335763 cites W2066204710 @default.
• W2974335763 cites W2069659635 @default.
• W2974335763 cites W2087800680 @default.
• W2974335763 cites W2092713600 @default.
• W2974335763 cites W2099218552 @default.
• W2974335763 cites W2100141308 @default.
• W2974335763 cites W2102004296 @default.
• W2974335763 cites W2102939102 @default.
• W2974335763 cites W2104316189 @default.
• W2974335763 cites W2117239059 @default.
• W2974335763 cites W2117775530 @default.
• W2974335763 cites W2120431466 @default.
• W2974335763 cites W2123945948 @default.
• W2974335763 cites W2125702566 @default.
• W2974335763 cites W2134444110 @default.
• W2974335763 cites W2134878729 @default.
• W2974335763 cites W2137853125 @default.
• W2974335763 cites W2138692147 @default.
• W2974335763 cites W2150134401 @default.
• W2974335763 cites W2151082560 @default.
• W2974335763 cites W2157549109 @default.
• W2974335763 cites W2161109798 @default.
• W2974335763 cites W2163940216 @default.
• W2974335763 cites W2169965478 @default.
• W2974335763 cites W2226110706 @default.
• W2974335763 cites W2288763477 @default.
• W2974335763 cites W2290950904 @default.
• W2974335763 cites W2414548406 @default.
• W2974335763 cites W2415372857 @default.
• W2974335763 cites W2552099557 @default.
• W2974335763 cites W2559059115 @default.
• W2974335763 cites W2560367415 @default.
• W2974335763 cites W2574190322 @default.
• W2974335763 cites W2591481727 @default.
• W2974335763 cites W2604743350 @default.
• W2974335763 cites W2613462750 @default.
• W2974335763 cites W2655262992 @default.
• W2974335763 cites W2791308824 @default.
• W2974335763 cites W2791333261 @default.
• W2974335763 cites W2795277327 @default.
• W2974335763 cites W2883407846 @default.
• W2974335763 cites W2896846857 @default.
• W2974335763 cites W3144968780 @default.
• W2974335763 doi "https://doi.org/10.1186/s13058-019-1195-z" @default.
• W2974335763 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6751874" @default.
• W2974335763 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31533777" @default.
• W2974335763 hasPublicationYear "2019" @default.
• W2974335763 type Work @default.
• W2974335763 sameAs 2974335763 @default.
• W2974335763 citedByCount "19" @default.
• W2974335763 countsByYear W29743357632020 @default.
• W2974335763 countsByYear W29743357632021 @default.
• W2974335763 countsByYear W29743357632022 @default.
• W2974335763 countsByYear W29743357632023 @default.
• W2974335763 crossrefType "journal-article" @default.
• W2974335763 hasAuthorship W2974335763A5004725639 @default.
• W2974335763 hasAuthorship W2974335763A5006511628 @default.
• W2974335763 hasAuthorship W2974335763A5010152267 @default.
• W2974335763 hasAuthorship W2974335763A5016401289 @default.
• W2974335763 hasAuthorship W2974335763A5019569585 @default.
• W2974335763 hasAuthorship W2974335763A5025238669 @default.
• W2974335763 hasAuthorship W2974335763A5025842545 @default.
• W2974335763 hasAuthorship W2974335763A5042649658 @default.
• W2974335763 hasAuthorship W2974335763A5043895722 @default.
• W2974335763 hasAuthorship W2974335763A5051034956 @default.
• W2974335763 hasAuthorship W2974335763A5059201728 @default.
• W2974335763 hasAuthorship W2974335763A5062635658 @default.

• next